MLH1 and gastric cancer: Interestingly, methylation of MLH1 predicted poor OS for advanced-stage GC patients, especially when combined with loss of oncosuppressor O(6)-methylguanine-DNA methyltransferase in two different cohorts of 135 and 68 GC patients (MGMT), while it was found to be a biomarker of better prognosis in resectable GC patients [59,60].